New Developments in Alzheimer's Treatment

Session Description:

Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. The AD treatment pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. It’s been more than 18 years since the FDA last approved an Alzheimer’s drug. However, over the past 5 years there has been research and development emphasis on non‐amyloid targets, including candidate treatments for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. Some interventions look to slow down the progression of AD, suggesting that treatment could turn AD from a fatal disease into a chronic condition. In addition, there has been a marked growth in repurposed agents in the pipeline. Affordability will also be an important consideration as new AD treatments are estimated to come to market at over $50,000 per year per patient— not including the cost of the PET scans and the neurology/radiology teams to monitor side effects.

In this session, faculty will review the pipeline of drugs and biologics in clinical trials for the treatment of AD and call attention to notable considerations for management.

Learning Objectives:

At the completion of this activity, participants should be able to:
  • Describe how the recognition, diagnosis, management, and treatment of Alzheimer’s disease is evolving.
  • Identify at least one emerging treatment for AD.
  • Describe a key managed care consideration around access and affordability of novel treatments.


Judy Huang, PharmD
Clinical Pharmacist, Consultant
Cambia Health Solutions
Portland, OR

Pierre Tariot, MD
Banner Alzheimer's Institute and University of Arizona College of Medicine 
Phoenix, AZ

Schedule of Educational Activity:

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation.


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE UAN:0233-0000-21-012-H01-P • Activity Type: Knowledge-Based
Contact Hours: 1
Release Date: May 5, 2021 •  Expiration Date: December 31, 2022
Activity Fee: $15 for members and $30 for non-members

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP 2021 Virtual.CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements:

System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for continuing education online learning activities.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-21-012-H01-P 1 Contact Hour April 14, 2021 - December 31, 2022